Clinical Trials for Esophageal Cancer

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.

ClinicalTrials.gov ID: NCT06242470

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.

ClinicalTrials.gov ID: NCT06239194

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.

ClinicalTrials.gov ID: NCT05902988

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.

ClinicalTrials.gov ID: NCT06747585

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.

ClinicalTrials.gov ID: NCT06781983

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.

ClinicalTrials.gov ID: NCT06943521

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.

ClinicalTrials.gov ID: NCT06710756

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable advanced/metastatic solid tumors (NSCLC, HNSCC, ESCC, left‑sided CRC) receive ALX2004 monotherapy, an investigational EGFR‑targeted antibody–drug conjugate carrying a topoisomerase I inhibitor payload designed for bystander effect. Excludes candidates for curative local therapy, rapidly progressive disease, short life expectancy, and prior exposure to topoisomerase I inhibitor ADCs.

ClinicalTrials.gov ID: NCT07085091

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT07109726

A Phase I/II Trial of Cabozantinib in Combination with Durvalumab (MEDI4736) with or Without Tremelimumab in Patients with Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.

ClinicalTrials.gov ID: NCT03539822